Skip to Content

Scott E. Evans, M.D., F.C.C.P.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Pulmonary Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Faculty, Institute of Biosciences and Technology, Texas A&M University, Houston, TX
Adjunct Professor, School of Medicine, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico
Regular Faculty Member, Program in Immunology and Program in Clinical and Translational Sciences, The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Graduate Faculty, Texas A&M Health Science Center School of Graduate Studies, College Station, TX

Research Interests

The entirety of my professional effort, both laboratory and clinical, is focused on the mechanisms that prevent humans from universally succumbing to the microbial pathogens they inhale or aspirate every day. In particular, I am interested in how non-HIV immunocompromised patients respond to the presence of respiratory pathogens. My goal is to exploit these native mechanisms to provide more comprehensive protection during episodes of peak vulnerability, such as when cancer patients receive chemotherapy. My laboratory is currently engaged full-time in mechanistic studies intended to unravel the means by which our recently described phenomenon of inducible resistance protects against pneumonia. Our available data indicate that this protective response occurs via antimicrobial product generation from treated respiratory epithelial cells, rather than through the typical leukocyte effectors of the innate immune system. My long term objective is to develop a research program focused on discovery and manipulation of epithelium-derived antimicrobial mediators that can ultimately be translated for clinical benefit.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 1100
Houston, TX 77030
Room Number: IBT7.705
Phone: 713-563-7433
Fax: 713-563-0411

Education & Training

Degree-Granting Education

1999 University of Texas Medical School, San Antonio, TX, MD, Medicine
1994 University of Texas, Austin, TX, BA, Plan II Honors Program

Postgraduate Training

7/2004-9/2005 Administrative (Chief) Fellow, Pulmonary Medicine, Mayo Graduate School of Medicine, Rochester, MN, Ulrich Specks, MD
6/2002-9/2005 Clinical Fellowship, Pulmonary & Critical Care Medicine, Mayo Graduate School of Medicine, Rochester, MN, Ulrich Specks, MD
1/2002-4/2004 Clinician-Investigator Research Training Program, Mayo Graduate School of Medicine, Rochester, MN, Andrew H Limper, MD
6/1999-6/2002 Clinical Internship and Residency, Internal Medicine, Mayo Graduate School of Medicine, Rochester, MN, Henry J Schultz, MD

Honors and Awards

2014 Cyrus Scholar Award, Cyrus Family Foundation
2014 Presidential Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center
2013 Distinguished Paper Award, The University of Texas MD Anderson Division of Internal Medicine
2013 NIH Director's New Innovator Award, NIH Office of the Director
2010 Cyrus Scholar Award, Cyrus Family Foundation
2008 Charles E. Culpeper Scholarship in Medical Science, Partnership for Cures/Culpeper Foundation
2008 Fellow, American College of Chest Physicians
2008 Physician-Scientist Award, The University of Texas MD Anderson Cancer Center
2007 Career Development Award, University of Texas Centers for Clinical and Translational Science
2005 Travel Grant, American Thoracic Society
2004 Burgher Family Endowed Pulmonary Fellowship Award
2003 Scholar Award, GlaxoSmithKline
2003 Second Place, National CHEST Challenge, American College of Chest Physicians
2003 Trainee Travel Award, Clinical Research, American Federation for Medical Research
2003 Trainee Travel Award, Experimental Biology, Federation of American Societies for Experimental Biology
2003 Young Investigator Award, ACCP Chest Foundation
2002 Graduation Rank #1, Mayo Internal Medicine Residency Program
2002 Outstanding Achievement Award, Mayo Internal Medicine Residency Program
2002 Trainee Travel Award, Clinical Research, American Federation for Medical Research
2002 Travel Award, Combined Annual Meeting, Central Society for Clinical Research
2002 Young Investigator Endowed Fellowship, Hartz Foundation
2001 Travel Award, 4th Annual International LAM Research Conference, NHLBI/LAM Foundation
1999 Holt Leadership Award
1998 Alpha Omega Alpha Honor Medical Society
1997 National Achievement Award, American Medical Association/GlaxoWellcome
1996 Certificate of Excellence for Outstanding Service, Texas State Senate
1993 Order of Omega Academic Honor Society
1992 Theta Award for Academic Excellence, University of Texas at Austin
1990-1994 Terry Foundation Scholar

Professional Memberships

Alpha Omega Alpha Honor Medical Society
Life Member, 1998-present
American College of Chest Physicians
Fellow, 2007-present
American College of Physicians-American Society of Internal Medicine
Member, 2003-present
American Medical Association
Member, 1995-present
American Thoracic Society
Member, 2005-present
Society of Critical Care Medicine
Member, 2002-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Gonzalez C, Johnson T, Rolston K, Merriman K, Warneke C, Evans S. Predicting pneumonia mortality using CURB-65, PSI, and patient characteristics in patients presenting to the emergency department of a comprehensive cancer center. Cancer Med 3(4):962-70, 8/2014. e-Pub 5/7/2014. PMID: 24802800.
2. Gonzalez CE, Johnson TN, Evans S, Kidin LM, George S, Haq S, Dejesus AY, Walters R, Rolston K. Assessing compliance with established pneumonia core measures at a comprehensive cancer center. J Healthc Qual. e-Pub 3/16/2014. PMID: 24629128.
3. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS, Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM, Moghaddam SJ, Karmouty-Quintana H, Blackburn MR, Drouin SM, Davis CW, Terrell KA, Grubb BR, O'Neal WK, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM, Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ, Schwartz DA, Boucher RC, Dickey BF, Evans CM. Muc5b is required for airway defence. Nature 505(7483):412-6, 1/16/2014. e-Pub 12/8/2013. PMCID: PMC4001806.
4. Cleaver JO, You D, Michaud DR, Pruneda FA, Juarez MM, Zhang J, Weill PM, Adachi R, Gong L, Moghaddam SJ, Poynter ME, Tuvim MJ, Evans SE. Lung epithelial cells are essential effectors of inducible resistance to pneumonia. Mucosal Immunol 7(1):78-88, 1/2014. e-Pub 5/1/2013. PMCID: PMC3735803.
5. Alfaro VY, Goldblatt DL, Valverde GR, Munsell MF, Quinton LJ, Walker AK, Dantzer R, Varadhachary A, Scott BL, Evans SE, Tuvim MJ, Dickey BF. Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands. Front Pharmacol 5:8, 2014. e-Pub 2/6/2014. PMCID: PMC3915096.
6. Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, Ost DE. Pneumonia during Remission Induction Chemotherapy in Patients with Acute Leukemia. Ann Am Thorac Soc 10(5):432-40, 10/2013. e-Pub 8/29/2013. PMCID: PMC3960911.
7. Tuvim MJ, Clement CG, Huang ES, Cote GJ, Evans SE, Lei X, Deftos LJ, Gagel RF, Dickey BF. Deletion of the gene encoding calcitonin and CGRPα does not affect the outcome of severe infection in mice. Am J Respir Cell Mol Biol 49(1):151-5, 7/2013. e-Pub 3/22/2013. PMCID: PMC3727888.
8. Drake MG, Evans SE, Dickey BF, Fryer AD, Jacoby DB. TLR2/6 and TLR9 Agonists Suppress Viral Replication but not Airway Hyperreactivity in Guinea Pigs. Am J Respir Cell Mol Biol 48(6):790-6, 6/2013. e-Pub 2/2013. PMCID: PMC3727870.
9. Evans SE, Kottom TJ, Pagano RE, Limper AH. Primary alveolar epithelial cell surface membrane microdomain function is required for Pneumocystis β-glucan-induced inflammatory responses. Innate Immun 18(5):709-16, 10/2012. e-Pub 2/14/2012. PMCID: PMC3645441.
10. Tuvim MJ, Gilbert BE, Dickey BF, Evans SE. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One 7(1):e30596, 2012. e-Pub 1/27/2012. PMCID: PMC3267724.
11. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: A Prospective 2-Year Study. Cancer 117(15):3424-33, 8/1/2011. e-Pub 1/18/2011. PMID: 21246537.
12. Evans SE, Tuvim MJ, Fox CJ, Sachdev N, Gibiansky L, Dickey BF. Inhaled innate immune ligands to prevent pneumonia. Br J Pharmacol 163(1):195-206, 5/2011. e-Pub 1/2011. PMCID: PMC3085878.
13. Duggan JM, You D, Cleaver JO, Larson DT, Garza RJ, Guzmn Pruneda FA, Tuvim MJ, Zhang J, Dickey BF, Evans SE. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol 186(10):5916-26, 5/2011. e-Pub 4/2011. PMID: 21482737.
14. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, Dickey BF, Moghaddam SJ. Interleukin 6 But Not T Helper 2 Cytokines Promotes Lung Carcinogenesis. Cancer Prev Res (Phila) 4(1):51-64, 1/2011. e-Pub 11/22/2010. PMCID: PMC3058282.
15. Evans SE, Leventakos K, Ben-Ami R, You D, Thakkar SG, Lewis RE, Kontoyiannis DP. Toll-deficient Drosophila are resistant to infection by Pneumocystis spp. additional evidence of specificity to mammalian hosts. Virulence 1(6). e-Pub 11/2010. PMCID: PMCPMID21178507.
16. Evans SE, Tuvim MJ, Zhang J, Larson DT, Garcia CD, Martinez Pro S, Coombes KR, Dickey BF. Host lung gene expression patterns predict infectious etiology in a mouse model of pneumonia. Respir Res 11(1). e-Pub 7/2010. PMCID: PMCPMID20653947.
17. Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Hk M, Xu Y, Tuvim MJ, Dickey BF. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 42(1):40-50, 1/2010. e-Pub 3/2009. PMCID: PMC2809220.
18. Clement CG, Tuvim MJ, Evans CM, Tuvin DM, Dickey BF, Evans SE. Allergic lung inflammation alters neither susceptibility to Streptococcus pneumoniae infection nor inducibility of innate resistance in mice. Respir Res 10(10):70, 2009. PMCID: PMC2724420.
19. Tuvim MJ, Evans SE (Co-First Author), Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One 4(1):e4176, 2009. e-Pub 1/2009. PMCID: PMC2613561.
20. Clement CG, Evans SE (Co-First Author), Evans CM, Hawke D, Kobayashi R, Reynolds PR, Moghaddam SJ, Scott BL, Melicoff E, Adachi R, Dickey BF, Tuvim MJ. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 177(12):1322-30, 6/2008. e-Pub 4/2008. PMCID: PMC2427056.
21. Evans SE, Hahn PY, McCann F, Kottom TJ, Pavlovic' ZV, Limper AH. (Cover Article) Pneumocystis cell wall β-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-ĸB-dependent mechanisms. Am J Respir Cell Mol Biol 32(6):490-7, 6/2005. e-Pub 3/2005. PMCID: PMC2715319.
22. Gilman G, Evans SE, Hansen WH, Barnes ME, Klarich KW. Evaluation of right pulmonary artery obstruction by echocardiography in a 32-year-old woman with suggested histoplasmosis. J Am Soc Echocardiogr 18(5):490-1, 5/2005. PMCID: PMCPMID15891762.
23. Evans SE, Colby TV, Ryu JH, Limper AH. Transforming growth factor-β1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. Chest 125(3):1063-70, 3/2004. PMCID: PMCPMID15006970.
24. Hahn PY, Evans SE, Kottom TJ, Standing JE, Pagano RE, Limper AH. Pneumocystis carinii cell wall β-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem 278(3):2043-50, 1/2003. PMCID: PMCPMID12419803.
25. Limper AH, Lebron F, Evans SE, Hahn RY. Pneumocystis carinii: cell wall β-glucan-mediated pulmonary inflammation. J Eukaryot Microbiol 50 Suppl:646, 2003. PMCID: PMCPMID14736200.

Invited Articles

1. Evans SE. (Selected for ATS CME program) ATS Virtual Symposium: Coping with Candida infections. Proc Am Thorac Soc 7(3):197-203, 5/2010. PMID: 20463248.
2. Evans SE, Xu Y, Tuvim MJ, Dickey BF. Inducible innate resistance of lung epithelium to infection. Annu Rev Physiol 72:413-35, 3/2010. PMID: 20148683.
3. Safdar A, Shelburne SA, Evans SE, Dickey BF. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf 8(4):435-49, 7/2009. PMID: 19538104.
4. Evans SE, Scanlon PD.. Current practice in pulmonary function testing. Mayo Clin Proc 78(6):758-763, 2003. PMCID: PMCPMID12934788.

Book Chapters

1. Evans SE, Safdar A. Pneumonia in the Critically Ill Cancer Patient. In: Cancer Critical Care. Ed(s) Pravinkumar SE, et al. Springer: New York. In Press.
2. Evans SE, Safdar A. Pneumonia and Other Lung Infections. In: Principles and Practice of Cancer Infectious Diseases. Ed(s) Safdar A. Humana Press: New York, 2011.
3. Shannon VR, Evans SE, et al. Respiratory Complications. In: Holland Frei Cancer Medicine, 8th Edition. Ed(s) Hong WK, Bast RC, et al. BC Decker: Columbia, 2010.
4. Evans SE, Scanlon PD, Culver BH. Pulmonary Function Testing. In: Comprehensive Respiratory Medicine, 3rd Edition, 3. Ed(s) Albert AK, Spiro SG, and Jett JR. Elsevier: Philadelphia, PA, 147-155, 2008.
5. Evans SE, Limper AH. Chemotherapy-Induced Lung Disease - An Evidence-Based Approach. In: Oncology: An Evidence-Based Approach. Ed(s) Ganz PA, Hayes SP, Kinsella T, Pass HI, Schiller JH, Stone R, Stretcher V.,. Springer-Verlag: New York, 1401-1410, 2005.
6. Evans SE, Limper AH. HIV: North American Perspective. In: Tropical and Parasitic Infections in the ICU. Ed(s) Feldman C and Sarosi GA. Kluwer Academic Publishers: Norwell, MA, 127-144, 2004.

Grant & Contract Support

Title: Epithelial mechanisms of inducible resistance to AML-associated pneumonia
Funding Source: NIH/NHLBI
Role: Principal Investigator
Duration: 1/1/2014 - 12/31/2018
Title: Cyrus Scholar Award
Funding Source: The Cyrus Family Foundation
Role: Principal Investigator
Duration: 11/1/2013 - 10/31/2016
Title: Inducible epithelial antiviral resistance to prevent asthma
Funding Source: NIH/NHLBI
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2018
Title: Mechanisms of inducible epithelial resistance to cancer-related pneumonia
Funding Source: TJ Martell Foundation
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2013
Title: Expanding the market and success rates for myeloablative cancer treatments using PUL-042, an innate immune stimulant
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Collaborator
Principal Investigator: Brenton Scott
Duration: 6/1/2012 - 5/30/2015

Last updated: 10/1/2014